Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm，Single Center，Prospective，Phase II Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy for Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

NCT06170697 is registered in ClinicalTrials.gov with Cancer Institute and Hospital, Chinese Academy of Medical Sciences as lead sponsor.

NCT NCT06170697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06170697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm，Single Center，Prospective，Phase II Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy for Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
Lead sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase
Phase 2
Overall status
Unknown status
Start date
March 1, 2023
Completion date
July 31, 2025
Enrollment
46 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma